Combination of Oral WX-671 Plus Capecitabine vs. Capecitabine Monotherapy in First-line Her2-negative Metastatic Breast Cancer
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Lori Goldstein, MD
Dept. of Medical Oncology, Division of Medical Science, Fox Chase Cancer Center, 7701 Burholme Avenue, Philadelphia, Pennsylvania 19111, USA
Principal Investigator - Nadia Harbeck, MD
Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Uniklinik Köln
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
20 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Az Klina, Oncology Department
Brasschaat, Belgium
- Institut Jules Bordet Oncologie Médicale
Brussels, Belgium
- Chu de Liège, Domaine Universitaire de Sart-Tilman, Oncology Department
Liège, Belgium
- Irmandade de Misericórdia Da Santa Casa de Porto Alegre
Porto Alegre, Brazil
- Instituto Nacional Do Câncer - Inca
Rio de Janeiro, Brazil
- Instituto Brasileiro de Controle Do Câncer - Ibcc
São Paulo, Brazil
- Gemeinschaftspraxis Dr. Brudler, Dr. Heinrich, Dr. Bangerter
Augsburg, Germany
- Klinik Und Poliklinik Für Frauenheilkunde Und Geburtshilfe, Uniklinik Köln
Cologne, Germany
- Universitätsklinikum Essen, Innere Klinik Und Poliklinik (tumorforschung)
Essen, Germany
- Uniklinik Frankfurt, Zentrum Der Frauenheilkunde Und Geburtshilfe
Frankfurt am Main, Germany
- Universitätsklinikum Der Martin-Luther-Universität Halle-Wittenberg, Poliklinik Gynäkologie
Halle, Germany
- Department of Obstetrics and Gynecology, Technical University
Munich, Germany
- Bethesda Kh
Mönchengladbach, Germany
- Davidof Center, Rabin Medical Center, Department of Oncology
Petah Tikva, Israel
- Kaplan Medical Center, Department of Oncolocy
Rehovot, Israel
- Sheba Medical Center, Department of Oncology
Tel Litwinsky, Israel
- Assaf Harofeh Medical Center, Department of Oncology
Ẕerifin, Israel
- Montefiore Medical Center Weiler Division Department
New York, New York, United States
- Universitys Hospital Case Medical Center
Cleveland, Ohio, United States
- Fox Chase Cancer Center
Philadelphia, Pennsylvania, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 31 Jul 2008
- Primary completion
- 31 Dec 2011
- Completion
- 30 Apr 2012
- Last update posted
- 28 Feb 2014
- Registered enrollment
- 132
- Registry id
- NCT00615940
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.